Traws Pharma corporate deck touts bird flu TXM data, COVID plans, $15.9M cash

Traws Pharma, Inc.

TXM bird flu: 100% survival in mice, dose-dependent survival in ferrets; single dose maintained plasma >EC90 for ~3 weeks in Phase 1.
Pursuing FDA Animal Rule for bird flu; FDA meeting granted, briefing package submitted April 24, 2025.
COVID candidate ratutrelvir: ritonavir-independent 10-day regimen; briefing document planned for June 2025.
Cash $15.9M as of March 31, 2025, expected to fund operations into Q1 2026.
Legacy oncology assets (rigosertib, narazaciclib) remain; pursuing business development exit strategies.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.